Skip to Main content


Researcher identifiers

Social networks

Export Publications

Export the displayed publications:
Number of documents


Dr Christophe A. Girard

Situation et Adresse professionnelle actuelle

Chargé de Recherche 1ere classe CNRS

Centre Méditerranéen de Médecine Moléculaire (C3M)

Equipe 11 : 'Microenvironnement, signalisation et Cancer'

INSERM U1065, Bâtiment Archimed,

151 Route de Saint Antoine de Ginestière

BP2 3194

06204 Nice

email :

Tel : 33 4 89 06 42 25

Fax : 33 4 89 06 42 21

Internet :


Journal articles23 documents

  • Christopher Rovera, Ilona Berestjuk, Margaux Lecacheur, Cassandre Tavernier, Serena Diazzi, et al.. Secretion of IL1 by Dedifferentiated Melanoma Cells Inhibits JAK1-STAT3-Driven Actomyosin Contractility of Lymph Node Fibroblastic Reticular Cells. Cancer Research, American Association for Cancer Research, 2022, 82 (9), pp.1774-1788. ⟨10.1158/0008-5472.CAN-21-0501⟩. ⟨inserm-03674501⟩
  • Margaux Lecacheur, Christophe A. Girard, Marcel Deckert, Sophie Tartare-Deckert. Échappement thérapeutique du mélanome : la piste biomécanique. médecine/sciences, EDP Sciences, 2020, 36 (11), pp.961-965. ⟨10.1051/medsci/2020201⟩. ⟨hal-02991398⟩
  • Christophe Girard, Margaux Lecacheur, Rania Ben Jouira, Ilona Berestjuk, Serena Diazzi, et al.. A Feed-Forward Mechanosignaling Loop Confers Resistance to Therapies Targeting the MAPK Pathway in BRAF-Mutant Melanoma. Cancer Research, American Association for Cancer Research, 2020, 80 (10), pp.1927-1941. ⟨10.1158/0008-5472.CAN-19-2914⟩. ⟨inserm-02889519⟩
  • Laurie Signetti, Nelli Elizarov, Méliné Simsir, Agnès Paquet, Dominique Douguet, et al.. Inhibition of patched drug efflux increases vemurafenib effectiveness against resistant braf(V600E) melanoma. Cancers, MDPI, 2020, 12 (6), pp.1500. ⟨10.3390/cancers12061500⟩. ⟨hal-02884136⟩
  • M. Rathore, Christophe Girard, M. Ohanna, M. Tichet, R. Ben Jouira, et al.. Cancer cell-derived long pentraxin 3 (PTX3) promotes melanoma migration through a toll-like receptor 4 (TLR4)/NF-κB signaling pathway. Oncogene, Nature Publishing Group, 2019, 38 (30), pp.5873-5889. ⟨10.1038/s41388-019-0848-9⟩. ⟨hal-02323965⟩
  • Barbara Seitz-Polski, Guillaume Dolla, Christine Payré, Christophe Girard, Joel Polidori, et al.. Epitope Spreading of Autoantibody Response to PLA2R Associates with Poor Prognosis in Membranous Nephropathy. Journal of the American Society of Nephrology, American Society of Nephrology, 2016, 27, pp.1517-33. ⟨hal-01455661⟩
  • Christophe Girard, Barbara Seitz Seitz-Polski, Guillaume Dolla, Arnaud Augert, David Vindrieux, et al.. Nouveaux rôles physiopathologiques pour le récepteur PLA2R1 dans le cancer et la glomérulonéphrite extramembraneuse. médecine/sciences, EDP Sciences, 2014, 30 (5), pp.519-525. ⟨10.1051/medsci/20143005014⟩. ⟨hal-03016069⟩
  • David Vindrieux, Arnaud Augert, Christophe Girard, Delphine Gitenay, Helene Lallet-Daher, et al.. PLA2R1 Mediates Tumor Suppression by Activating JAK2. Cancer Research, American Association for Cancer Research, 2013, 73 (20), pp.6334-6345. ⟨10.1158/0008-5472.CAN-13-0318⟩. ⟨hal-02395807⟩
  • Hafid Ait Oufella, Alain Tedgui, Makoto Murakami, Olivier Herbin, Charlotte Lahoute, et al.. Group X Secreted Phospholipase A2 Limits the Development of Atherosclerosis in LDL Receptor–Null Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, American Heart Association, 2013, 33 (3), pp.466-473. ⟨10.1161/ATVBAHA.112.300309⟩. ⟨hal-03016106⟩
  • Arnaud Augert, David Vindrieux, Christophe Girard, Benjamin Le Calvé, Baptiste Gras, et al.. PLA2R1 kills cancer cells by inducing mitochondrial stress. Free Radical Biology and Medicine, Elsevier, 2013, 65, pp.969-977. ⟨10.1016/j.freeradbiomed.2013.08.177⟩. ⟨hal-02395811⟩
  • Christophe Girard. Control of Pancreatic β Cell Regeneration by Glucose Metabolism. Cell Metabolism, Elsevier, 2011, 13 (4), pp.440-449. ⟨10.1016/j.cmet.2011.02.012⟩. ⟨hal-03016133⟩
  • Chris Church, Christophe Girard, Lydia Teboul, Jens Brüning, P.M. Nolan, et al.. Overexpression of Fto leads to increased food intake and results in obesity. Nature Genetics, Nature Publishing Group, 2010, 42 (12), pp.1086-1092. ⟨10.1038/ng.713⟩. ⟨hal-03016713⟩
  • Makoto Murakami, Yoshitaka Taketomi, Christophe Girard, Kei Yamamoto, Gérard Lambeau. Emerging roles of secreted phospholipase A2 enzymes: Lessons from transgenic and knockout mice.. Biochimie, Elsevier, 2010, 92 (6), pp.561-82. ⟨10.1016/j.biochi.2010.03.015⟩. ⟨hal-00497527⟩
  • Christophe Girard. Expression of an activating mutation in the gene encoding the KATP channel subunit Kir6.2 in mouse pancreatic β cells recapitulates neonatal diabetes. Journal of Clinical Investigation, American Society for Clinical Investigation, 2009, ⟨10.1172/JCI35772⟩. ⟨hal-03016127⟩
  • Christophe Girard. Adjacent mutations in the gating loop of Kir6.2 produce neonatal diabetes and hyperinsulinism. EMBO Molecular Medicine, Wiley Open Access, 2009, 1 (3), pp.166-177. ⟨10.1002/emmm.200900018⟩. ⟨hal-03016139⟩
  • Christophe Girard. Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11. Nature Clinical Practice Neurology, Nature Publishing Group, 2007, 3 (11), pp.640-645. ⟨10.1038/ncpneuro0640⟩. ⟨hal-03016431⟩
  • Thomas Gerken, Christophe Girard, Frances M. Ashcroft. The Obesity-Associated FTO Gene Encodes a 2-Oxoglutarate-Dependent Nucleic Acid Demethylase. Science, American Association for the Advancement of Science (AAAS), 2007, 318 (5855), pp.1469-1472. ⟨10.1126/science.1151710⟩. ⟨hal-03016428⟩
  • Christophe Girard. Mechanism of action of a sulphonylurea receptor SUR1 mutation (F132L) that causes DEND syndrome. Human Molecular Genetics, Oxford University Press (OUP), 2007, 16 (16), pp.2011-2019. ⟨10.1093/hmg/ddm149⟩. ⟨hal-03016446⟩
  • Christophe Girard. Permanent Neonatal Diabetes Caused by Dominant, Recessive, or Compound Heterozygous SUR1 Mutations with Opposite Functional Effects. American Journal of Human Genetics, Elsevier (Cell Press), 2007, 81 (2), pp.375-382. ⟨10.1086/519174⟩. ⟨hal-03016441⟩
  • Andrei I. Tarasov, Christophe Girard, Frances M. Ashcroft. ATP Sensitivity of the ATP-Sensitive K + Channel in Intact and Permeabilized Pancreatic β-Cells. Diabetes, American Diabetes Association, 2006, 55 (9), pp.2446-2454. ⟨10.2337/db06-0360⟩. ⟨hal-03016460⟩
  • Peter Proks, Christophe Girard, Frances M. Ashcroft. Functional Effects of Mutations at F35 in the NH2-terminus of Kir6.2 (KCNJ11), Causing Neonatal Diabetes, and Response to Sulfonylurea Therapy. Diabetes, American Diabetes Association, 2006, 55 (6), pp.1731-1737. ⟨10.2337/db05-1420⟩. ⟨hal-03016732⟩
  • Kenju Shimomura, Christophe Girard, Frances M. Ashcroft. Mutations at the Same Residue (R50) of Kir6.2 (KCNJ11) That Cause Neonatal Diabetes Produce Different Functional Effects. Diabetes, American Diabetes Association, 2006, 55 (6), pp.1705-1712. ⟨10.2337/db05-1640⟩. ⟨hal-03016473⟩
  • Christophe Girard, Frances M. Ashcroft. Functional analysis of six Kir6.2 (KCNJ11) mutations causing neonatal diabetes. Pflügers Archiv European Journal of Physiology, Springer Verlag, 2006, 453 (3), pp.323-332. ⟨10.1007/s00424-006-0112-3⟩. ⟨hal-03016452⟩

Preprints, Working Papers, ...3 documents

  • S. Diazzi, A. Baeri, J. Fassy, M. Lecacheur, O. Marin-Bejar, et al.. Blockade of pro-fibrotic response mediated by the miR-143/-145 cluster prevents targeted therapy-induced phenotypic plasticity and resistance in melanoma. 2021. ⟨hal-03417405⟩
  • Christopher Rovera, Ilona Berestjuk, Margaux Lecacheur, Serena Diazzi, Aude Mallavialle, et al.. Invasive dedifferentiated melanoma cells inhibit JAK1-STAT3-driven actomyosin contractility of human fibroblastic reticular cells of the lymph node. 2021. ⟨hal-03417408⟩
  • Ilona Berestjuk, Margaux Lecacheur, Serena Diazzi, Christopher Rovera, Virginie Prod'Homme, et al.. Targeting DDR1 and DDR2 overcomes matrix-mediated melanoma cell adaptation to BRAF-targeted therapy. 2020. ⟨hal-03016761⟩